Burden of respiratory syncytial virus disease in infants and the potential value of maternal immunization in Greece.

ABSTRACT:

Objective

The objective was to assess the burden of respiratory syncytial virus (RSV) and evaluate the cost-effectiveness of maternal vaccination using the bivalent RSV prefusion F-protein (RSVpreF) vaccine to prevent RSV infections among Greek infants.

Methods

A Markov model was adapted from the perspective of a public payer to simulate the health and economic outcomes of RSV from birth to 1 year of age. Key inputs for the model, including vaccine efficacy, utility values, epidemiological data, and direct medical costs [prices in euros (€), 2024], were obtained from official sources. Model main outcomes were medically attended RSV cases, RSV-related deaths, quality-adjusted life-years (QALY) gained, direct medical costs and incremental cost-effectiveness ratios (ICER).

R

SUBMITTER: Gourzoulidis G 

PROVIDER: S-EPMC12307291 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature